<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03725865</url>
  </required_header>
  <id_info>
    <org_study_id>iNSC-81NK-01</org_study_id>
    <nct_id>NCT03725865</nct_id>
  </id_info>
  <brief_title>A Clinical Study of iNSC Intervent Cerebral Hemorrhagic Stroke</brief_title>
  <official_title>A Clinical Study of Intracerebral Transplantation of Human Peripheral Blood Derived Induced Neural Stem Cells for Cerebral Hemorrhagic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allife Medical Science and Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allife Medical Science and Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single centre、single arm、open-label，to investigate the safety and efficacy of&#xD;
      induction of neural stem cells transplantation in the brain&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent AE</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Stroke, Ischemic</condition>
  <arm_group>
    <arm_group_label>iNSC treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Induction of neural stem cells</intervention_name>
    <description>Brain injection iNSC</description>
    <arm_group_label>iNSC treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have the ability to understand the requirements of the study, provide written informed&#xD;
             consent, and comply with the study procedures.&#xD;
&#xD;
          2. Men and women 30-65 years old.&#xD;
&#xD;
          3. Women must have a negative serum pregnancy test, gestation age women practice an&#xD;
             acceptable method of contraception.&#xD;
&#xD;
          4. At least 12 months but no more than 60 months from time of hemorrhagic stroke, with a&#xD;
             motor neurological deficit.&#xD;
&#xD;
          5. Documented history of single hemorrhagic stroke in subcortical region of MCA or&#xD;
             lenticulostriate artery with or without cortical involvement, with correlated findings&#xD;
             by MRI.&#xD;
&#xD;
          6. Modified Rankin Score of 2, 3 or 4.&#xD;
&#xD;
          7. FMMS score of 55 or less, two evaluations at approximately 3 weeks apart prior to&#xD;
             surgery with less than +/- 5 point change in the FMMS.&#xD;
&#xD;
          8. Two evaluations at approximately 3 weeks apart prior to surgery with less than +/- 4&#xD;
             point change in the NIHSS.&#xD;
&#xD;
          9. Able and willing to undergo post-physical therapy/rehabilitation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any disabling psychological or psychiatric disorders which may confound the study.&#xD;
&#xD;
          2. History of more than one hemorrhagic stroke.&#xD;
&#xD;
          3. History of another major neurological disease or injury.&#xD;
&#xD;
          4. Cerebral soften lesion size &gt;5cm in any one measurement.&#xD;
&#xD;
          5. Myocardial infarction within the prior 3 months.&#xD;
&#xD;
          6. History of seizures or current use of antiepileptic medication.&#xD;
&#xD;
          7. History of peripheral nerve surgery, including Selective Dorsal Rhizotomy and&#xD;
             Contralateral Seventh Cervical Nerve Transfer.&#xD;
&#xD;
          8. Receipt of any investigational drug or device within 30 days.&#xD;
&#xD;
          9. Receipt of any cell infusion other than blood transfusion.&#xD;
&#xD;
         10. Any concomitant medical disease or condition noted below:&#xD;
&#xD;
               1. Coagulopathy.&#xD;
&#xD;
               2. Active or history of malignancy.&#xD;
&#xD;
               3. Primary or secondary immune deficiency.&#xD;
&#xD;
               4. Persistent MRI artifact or unable to undergo MRI.&#xD;
&#xD;
         11. Any condition that the Investigator or primary physician feels may interfere with&#xD;
             participation in the study or may endanger the subject.&#xD;
&#xD;
         12. Any condition that the surgeon feels may pose complications for the surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2018</study_first_posted>
  <last_update_submitted>October 29, 2018</last_update_submitted>
  <last_update_submitted_qc>October 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Hemorrhagic Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

